Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Atallah on the Clinical Implications of the QUAZAR AML-001 Trial in AML

July 16th 2021

Ehab L. Atallah, MD, discusses the clinical implications of the phase 3 QUAZAR AML-001 trial in acute myeloid leukemia.

Updates in the Treatment of Mantle Cell Lymphoma

July 16th 2021

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

FDA Grants Full Approval to Belumosudil for Chronic GVHD

July 16th 2021

The FDA has approved belumosudil for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease following failure of at least 2 prior lines of systemic therapy.

The Impact of Mutational Status on Treatment Considerations for MDS

July 16th 2021

James Foran, MD; Azra Raza, MD; and Gail Roboz, MD, discuss how mutation status in myelodysplastic syndrome may impact treatment considerations.

Pevonedistat Plus HMAs Provides a Promising Strategy in Higher-Risk MDS

July 16th 2021

Daniel Pollyea, MD, MS, discusses the current management of patients with higher-risk myelodysplastic syndrome, the data noted so far with pevonedistat in this paradigm, and other therapies positioned to improve outcomes for this patient population.

Developmental Interest in Allogeneic Placenta–Derived Cell Therapies Expands

July 16th 2021

Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.

Pevonedistat/Azacitidine Could Become New Frontline Standard for Higher-Risk MDS

July 15th 2021

David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.

FDA Lifts Partial Clinical Hold on Trial Examining CDK8/CDK19 Inhibitor RVU120 in AML, MDS

July 14th 2021

The FDA has lifted a partial clinical hold that was placed on a first-in-human, phase 1b trial evaluating RVU120 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

BiTEs: More Than a Nibble for Lymphoma and Myeloma

July 13th 2021

Despite the failure of several strategies to improve the outcomes of patients with newly diagnosed diffuse large B-cell lymphoma, there appears to be substantial and growing progress in the treatment of relapsed disease.

Eprenetapopt/Azacitidine Combo Elicits Promising Activity in TP53-Mutant MDS and AML

July 13th 2021

The combination of eprenetapopt and azacitidine demonstrated a promising safety profile as well as encouraging clinical activity in a high-risk population of patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 13th 2021

Potential implications for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with loncastuximab tesirine, an antibody-drug conjugate, based on early results demonstrated by the LOTIS-2 study.

Treatment Advances in Relapsed/Refractory DLBCL

July 13th 2021

A historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy.

Fedratinib for Patients With Primary Myelofibrosis

July 13th 2021

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

Ruxolitinib for Patients With Primary Myelofibrosis

July 13th 2021

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

Dr. Sallman on Unmet Treatment Needs in Higher-Risk MDS

July 12th 2021

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

Treatment Considerations in DLBCL

July 12th 2021

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

Treating Newly Diagnosed Patients With DLBCL

July 12th 2021

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

Clinical Considerations in the Diagnosis of Patients with MDS

July 9th 2021

Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center & Research Institute, discusses the importance of examining a patient’s complete blood count, nutritional status and bone marrow when considering a diagnosis of myelodysplastic syndrome.

Myelodysplastic Syndrome Diagnosis and Risk Assessment

July 9th 2021

Gail Roboz, MD; Azra Raza, MD; and Amy DeZern, MD, MHS, discuss the clinical considerations and risk assessments inherent to a diagnosis of myelodysplastic syndrome.

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

July 8th 2021

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).